These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. The pathophysiology of MASLD: an immunometabolic perspective. Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354 [TBL] [Abstract][Full Text] [Related]
14. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'. Li C; Wang T; Song J Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Younossi ZM; Golabi P; Paik J; Owrangi S; Yilmaz Y; El-Kassas M; Alswat K; Alqahtani SA Liver Int; 2024 Apr; 44(4):1061-1070. PubMed ID: 38305642 [TBL] [Abstract][Full Text] [Related]
16. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Zhao S; Guo Y; Yin X Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834 [TBL] [Abstract][Full Text] [Related]
17. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease. Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586 [TBL] [Abstract][Full Text] [Related]
18. Roles of Activin A and Gpnmb in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Liu H; Yerevanian A; Westerhoff M; Hastings MH; Guerra JRB; Zhao M; Svensson KJ; Cai B; Soukas AA; Rosenzweig A Diabetes; 2024 Feb; 73(2):260-279. PubMed ID: 37934943 [TBL] [Abstract][Full Text] [Related]
19. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma. Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646 [TBL] [Abstract][Full Text] [Related]
20. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Benedé-Ubieto R; Cubero FJ; Nevzorova YA Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]